Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Jun 8, 2021

(R) Cantargia receives regulatory approval to start clinical trial investigating nadunolimab and FOLFIRINOX in pancreatic cancer

May 26, 2021

(R) Annual General Meeting in Cantargia AB (publ)

May 26, 2021

(R) Cantargia publishes interim report for first quarter 2021

May 19, 2021

(R) Cantargia reports positive results in ongoing phase IIa clinical trial in pancreatic cancer using nadunolimab and chemotherapy

May 10, 2021

(R) Cantargia presents new preclinical data showing unique improvement of heart function in myocarditis using antibody CAN10

May 6, 2021

(R) Cantargia advance development of antibody CAN04 by a new clinical trial in triple negative breast cancer

Apr 28, 2021

Cantargia to arrange a live-streamed R&D Day and invite participants to a conference call presenting Q1 2021 results

Apr 27, 2021

(R) Notice of annual general meeting in Cantargia AB (publ)

Apr 26, 2021

(R) Cantargia presents new preclinical data on antibody CAN10 at IMMMUNOLOGY2021

Mar 19, 2021

(R) Cantargia reports positive preclinical safety and efficacy results in the CAN10 project

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye